ACS 患者 PCI 后短期 DAPT 继以氯吡格雷单药对比 12 个月 DAPT:STOPDAPT-2 ACS 随机临床试验
STOPDAPT-2 ACS 为日本 96 中心、开放标签随机试验,纳入 4169 例成功植入钴铬依维莫司洗脱支架的 ACS 患者,比较 1–2 个月 DAPT 后氯吡格雷单药与 12 个月 DAPT。12 个月主要复合终点(心血管或出血事件)发生率为 3.2% 对 2.8%,HR 1.14(95%CI 0.80–1.62),未达到非劣效(P=0.06)。
要点
- 1–2 个月 DAPT 后氯吡格雷单药对主要复合终点未证实非劣于 12 个月 DAPT
- 心血管事件数值上增加(HR 1.50,95%CI 0.99–2.26),出血事件减少(HR 0.46,95%CI 0.23–0.94)
- 疗效与安全性方向不一致,需进一步临床试验验证
核心结论
- 在成功 PCI 的 ACS 患者中,1–2 个月 DAPT 后氯吡格雷单药对净临床获益未达到非劣于标准 12 个月 DAPT,心血管事件数值增加而出血事件减少。
研究设计与样本
- 多中心、开放标签、随机临床试验,日本 96 个中心,2015 年 12 月至 2020 年 6 月入组 4169 例 ACS 并成功行 PCI 植入钴铬依维莫司洗脱支架的患者。
- 随机分为 1–2 个月 DAPT 后氯吡格雷单药组(n=2078)与 12 个月阿司匹林联合氯吡格雷 DAPT 组(n=2091)。
- 33 例撤回知情同意,纳入分析 4136 例,平均(SD)年龄 66.8(11.9)岁,女性 856 例(21%),4107 例(99.3%)完成 1 年随访。
主要发现
- 主要复合终点(12 个月心血管死亡、心肌梗死、任何卒中或确定支架血栓,或 TIMI 主要/次要出血):1–2 个月 DAPT 组 65/2058 例(3.2%),12 个月 DAPT 组 58/2057 例(2.8%)。
- 主要复合终点绝对差 0.37%(95%CI -0.68% 至 1.42%),HR 1.14(95%CI 0.80–1.62),非劣效性 P=0.06。
- 主要次要心血管终点:1–2 个月 DAPT 组 56 例(2.8%),12 个月 DAPT 组 38 例(1.9%),绝对差 0.90%(95%CI -0.02% 至 1.82%),HR 1.50(95%CI 0.99–2.26)。
- 主要次要出血终点:1–2 个月 DAPT 组 11 例(0.5%),12 个月 DAPT 组 24 例(1.2%),绝对差 -0.63%(95%CI -1.20% 至 -0.06%),HR 0.46(95%CI 0.23–0.94)。
关键数值与推荐
- 非劣效界值为风险比(HR)尺度上的 50%。
- 主要终点为 12 个月时心血管事件(心血管死亡、心肌梗死、任何卒中或确定支架血栓)或出血事件(TIMI 主要或次要出血)的复合终点。
临床怎么用
- ACS 患者成功 PCI 后采用 1–2 个月 DAPT 后氯吡格雷单药的策略未获本试验非劣效支持,决策时应权衡心血管缺血风险与出血风险。
- 本试验中短 DAPT 组出血减少但心血管事件数值增加,提示需个体化评估并等待进一步临床试验证据。
局限性
- 开放标签设计。
- 主要终点未达到非劣效,疗效与安全性结果方向不一致,需进一步临床试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Clopidogrel monotherapy after short dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) has not yet been fully investigated in patients with acute coronary syndrome (ACS). OBJECTIVE: To test the hypothesis of noninferiority of 1 to 2 months of DAPT compared with 12 months of DAPT for a composite end point of cardiovascular and bleeding events in patients with ACS. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, open-label, randomized clinical trial enrolled 4169 patients with ACS who underwent successful PCI using cobalt-chromium everolimus-eluting stents at 96 centers in Japan from December 2015 through June 2020. These data were analyzed from June to July 2021. INTERVENTIONS: Patients were randomized either to 1 to 2 months of DAPT followed by clopidogrel monotherapy (n = 2078) or to 12 months of DAPT with aspirin and clopidogrel (n = 2091). MAIN OUTCOMES AND MEASURES: The primary end point was a composite of cardiovascular (cardiovascular death, myocardial infarction [MI], any stroke, or definite stent thrombosis) or bleeding (Thrombolysis in MI major or minor bleeding) events at 12 months, with a noninferiority margin of 50% on the hazard ratio (HR) scale. The major secondary end points were cardiovascular and bleeding components of the primary end point. RESULTS: Among 4169 randomized patients, 33 withdrew consent. Of the 4136 included patients, the mean (SD) age was 66.8 (11.9) years, and 856 (21%) were women, 2324 (56%) had ST-segment elevation MI, and 826 (20%) had non-ST-segment elevation MI. A total of 4107 patients (99.3%) completed the 1-year follow-up in June 2021. One to 2 months of DAPT was not noninferior to 12 months of DAPT for the primary end point, which occurred in 65 of 2058 patients (3.2%) in the 1- to 2-month DAPT group and in 58 of 2057 patients (2.8%) in the 12-month DAPT group (absolute difference, 0.37% [95% CI, -0.68% to 1.42%]; HR, 1.14 [95% CI, 0.80-1.62]; P for noninferiority = .06). The major secondary cardiovascular end point occurred in 56 patients (2.8%) in the 1- to 2-month DAPT group and in 38 patients (1.9%) in the 12-month DAPT group (absolute difference, 0.90% [95% CI, -0.02% to 1.82%]; HR, 1.50 [95% CI, 0.99-2.26]). The major secondary bleeding end point occurred in 11 patients (0.5%) in the 1- to 2-month DAPT group and 24 patients (1.2%) in the 12-month DAPT group (absolute difference, -0.63% [95% CI, -1.20% to -0.06%]; HR, 0.46 [95% CI, 0.23-0.94]). CONCLUSIONS AND RELEVANCE: In patients with ACS with successful PCI, clopidogrel monotherapy after 1 to 2 months of DAPT failed to attest noninferiority to standard 12 months of DAPT for the net clinical benefit with a numerical increase in cardiovascular events despite reduction in bleeding events. The directionally different efficacy and safety outcomes indicate the need for further clinical trials. TRIAL REGISTRATION: ClinicalTrials.gov Identifiers: NCT02619760 and NCT03462498.
引用
- Watanabe, Morimoto, Natsuaki, et al. Comparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet Therapy With 12 Months of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome: The STOPDAPT-2 ACS Randomized Clinical Trial. JAMA Cardiol. 2022. PMID: 35234821. doi:10.1001/jamacardio.2021.5244
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。